全文获取类型
收费全文 | 87197篇 |
免费 | 7058篇 |
国内免费 | 878篇 |
专业分类
耳鼻咽喉 | 542篇 |
儿科学 | 1832篇 |
妇产科学 | 2293篇 |
基础医学 | 9534篇 |
口腔科学 | 1589篇 |
临床医学 | 6356篇 |
内科学 | 11155篇 |
皮肤病学 | 1287篇 |
神经病学 | 2643篇 |
特种医学 | 4715篇 |
外国民族医学 | 26篇 |
外科学 | 10766篇 |
综合类 | 1825篇 |
现状与发展 | 10篇 |
预防医学 | 3488篇 |
眼科学 | 560篇 |
药学 | 3271篇 |
11篇 | |
中国医学 | 302篇 |
肿瘤学 | 32928篇 |
出版年
2024年 | 120篇 |
2023年 | 4132篇 |
2022年 | 5949篇 |
2021年 | 6273篇 |
2020年 | 6664篇 |
2019年 | 4407篇 |
2018年 | 4163篇 |
2017年 | 4097篇 |
2016年 | 4069篇 |
2015年 | 4335篇 |
2014年 | 7567篇 |
2013年 | 5699篇 |
2012年 | 3970篇 |
2011年 | 3248篇 |
2010年 | 4613篇 |
2009年 | 4208篇 |
2008年 | 2072篇 |
2007年 | 2100篇 |
2006年 | 1704篇 |
2005年 | 1473篇 |
2004年 | 1117篇 |
2003年 | 1103篇 |
2002年 | 1169篇 |
2001年 | 1189篇 |
2000年 | 928篇 |
1999年 | 1021篇 |
1998年 | 933篇 |
1997年 | 698篇 |
1996年 | 681篇 |
1995年 | 630篇 |
1994年 | 464篇 |
1993年 | 387篇 |
1992年 | 315篇 |
1991年 | 337篇 |
1990年 | 330篇 |
1989年 | 379篇 |
1988年 | 400篇 |
1987年 | 325篇 |
1986年 | 231篇 |
1985年 | 196篇 |
1984年 | 165篇 |
1983年 | 149篇 |
1982年 | 172篇 |
1981年 | 155篇 |
1980年 | 137篇 |
1979年 | 106篇 |
1978年 | 78篇 |
1977年 | 65篇 |
1976年 | 76篇 |
1975年 | 55篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
《Journal of the American College of Radiology》2020,17(10):1207-1219
PurposeLobular neoplasia (LN) detected on breast core needle biopsy is frequently managed with surgical excision because of concern for undersampled malignancy. The authors performed a systematic review and meta-analysis to estimate the risk for upgrade to malignancy in the setting of imaging-concordant classic LN diagnosed on core biopsy.MethodsPubMed and Embase were searched for original articles published from 1998 to 2020 that reported rates of upgrade to malignancy for classic LN, including atypical lobular hyperplasia (ALH) and classic lobular carcinoma in situ (LCIS). Two reviewers extracted study data and assessed the following quality criteria: exclusion of variant LCIS, exclusion of imaging-discordant lesions, and outcome reporting for ≥70% of lesions. For studies meeting all criteria, pooled risks for upgrade to any malignancy (invasive carcinoma or ductal carcinoma in situ) and invasive malignancy for all LN, ALH, and LCIS were estimated using random-effects models.ResultsFor 65 full-text articles included in the review, the risk for upgrade to any malignancy ranged from 0% to 45%. Among the 16 studies that met all quality criteria for the meta-analysis, pooled risks for upgrade to any malignancy were 3.1% (95% confidence interval [CI], 1.8%-5.2%) for all LN, 2.5% (95% CI, 1.6%-3.9%) for ALH, and 5.8% (95% CI, 2.9%-11.3%) for LCIS. Risks for upgrade to invasive malignancy were 1.3% (95% CI, 0.7%-2.4%) for all LN, 0.4% (95% CI, 0.0%-4.2%) for ALH, and 3.5% (95% CI, 2.0%-5.9%) for LCIS.ConclusionsThe risk for upgrade to malignancy for LN found on breast biopsy is low. Imaging surveillance can likely be offered as an alternative to surgical management for LN, particularly for ALH. 相似文献
92.
《Clinical gastroenterology and hepatology》2022,20(5):1112-1121.e4
- Download : Download high-res image (419KB)
- Download : Download full-size image
93.
《Current problems in cardiology》2022,47(12):101367
Percutaneous balloon mitral valvuloplasty (PBMV) is primarily performed for rheumatic mitral stenosis (MS). Therefore, limited data exist on PBMV in countries with a low incidence of rheumatic disease. Using the Nationwide Readmission Database, we examined trends in in-hospital mortality and 30-day readmission among patients who received PBMV for rheumatic and non-rheumatic MS. We also examined the change in 90-day hospitalization rate before vs after PBMV. Between 2016 and 2019, there were 1109 hospitalizations in which patients received PBMV for rheumatic (n = 955, 86.1%) vs non-rheumatic MS (n = 154, 13.9%). The all-cause in-hospital mortality for rheumatic and non-rheumatic MS did not change over time (0.9% → 2.0%, P = 0.94, and 5.9% → 9.5%, P = 0.09 respectively). Similarly, the 30-day readmission for patients with rheumatic and non-rheumatic MS did not change over time (12.4% → 9.9%, P = 0.26, and 4.4% → 10.5%, P = 0.30, respectively). The 90-day all-cause hospitalization rate remained the same before vs after PBMV for rheumatic and non-rheumatic MS (25.5% → 21.8%; P = 0.14, and 24.0% → 33.7%; P = 0.19, respectively). Although no statistically significant change was noted over time for trends in in-hospital mortality, 30-day readmission, or even in the change in 90-day all-cause hospitalizations before and after PBMV for both types of MS, among those with non-rheumatic MS, there was a signal of an increase in the in-hospital mortality, and 30-day readmission, even more, there was 29% relative increase in 90-day hospitalizations after PBMV. Future studies are needed to examine the role of PBMV in patients with non-rheumatic MS. 相似文献
94.
95.
96.
97.
98.
Hui-Ju Ch’ang 《World journal of hepatology》2015,7(16):2029-2040
The success of sorafenib in prolonging survival of patients with hepatocellular carcinoma (HCC) makes therapeutic inhibition of angiogenesis a component of treatment for HCC. To enhance therapeutic efficacy, overcome drug resistance and reduce toxicity, combination of antiangiogenic agents with chemotherapy, radiotherapy or other targeted agents were evaluated. Nevertheless, the use of antiangiogenic therapy remains suboptimal regarding dosage, schedule and duration of therapy. The issue is further complicated by combination antiangiogenesis to other cytotoxic or biologic agents. There is no way to determine which patients are most likely respond to a given form of antiangiogenic therapy. Activation of alternative pathways associated with disease progression in patients undergoing antiangiogenic therapy has also been recognized. There is increasing importance in identifying, validating and standardizing potential response biomarkers for antiangiogenesis therapy for HCC patients. In this review, biomarkers for antiangiogenesis therapy including systemic, circulating, tissue and imaging ones are summarized. The strength and deficit of circulating and imaging biomarkers were further demonstrated by a series of studies in HCC patients receiving radiotherapy with or without thalidomide. 相似文献
99.
《Vaccine》2020,38(2):115-118
Different strategies have been proposed to overcome maternally derived antibody (MDA) interference with canine parvovirus type 2 (CPV-2) immunisation, including intranasal vaccination, which presents some practical limitations. In the present study, the results of the oral administration of a commercial CPV-2b modified live virus (MLV) vaccine in pups with MDA are reported. The CPV-2b vaccine was orally administered to 14 6-week-old pups with a bait. Blood samples and rectal swabs were collected at different days post-vaccination (dpv) to determine CPV-2 antibody titres and DNA loads. Thirteen pups were positive to serological and virological tests after the first vaccination and one pup became positive after the second vaccine administration. The findings of this study suggest that systemic immunity against CPV-2 may be achieved by the use of an MLV CPV-2b vaccine administered orally even in the presence of MDA titres that usually interfere with vaccination. 相似文献
100.
《Neuro-Chirurgie》2022,68(3):262-266
BackgroundThe prognosis for patients with recurrent glioblastoma (GBM) is dismal, and the question of repeat surgery at time of recurrence is common. Re-operation in the management of these patients remains controversial, as there is no randomized evidence of benefit. An all-inclusive pragmatic care trial is needed to evaluate the role of repeat resection.Methods3rGBM is a multicenter, pragmatic, prospective, parallel-group randomized care trial, with 1:1 allocation to repeat resection or standard care with no repeat resection. To test the hypothesis that repeat resection can improve overall survival by at least 3 months (from 6 to 9 months), 250 adult patients with prior resection of pathology-proven glioblastoma for whom the attending surgeon believes repeat resection may improve quality survival will be enrolled. A surrogate measure of quality of life, the number of days outside of hospital/nursing/palliative care facility, will also be compared. Centers are invited to participate without financial compensation and without contracts. Clinicians may apply to local authorities to approve an investigator-led in-house trial, using a common protocol, web-based randomization platform, and simple standardized case report forms.DiscussionThe 3rGBM trial is a modern transparent care research framework with no additional risks, tests, or visits other than what patients would encounter in normal care. The burden of proof remains on repeat surgical management of recurrent GBM, because this management has yet to be shown beneficial. The trial is designed to help patients and surgeons manage the uncertainty regarding optimal care.Clinical Trial Registrationhttp://www.clinicaltrials.gov. Unique identifier: NCT04838782. 相似文献